Stories

At the 2nd National Summit on Nicotine and Harm Reduction in Pasay City on October 1, consumer groups, industry representatives and medical experts urged evidence-based, risk-proportionate taxation and regulation of smoke-free nicotine products. As the Philippine government considers policy changes for vaping and heated tobacco products, participants argued that these alternatives should not automatically face the same taxes as combustible cigarettes, citing differences in associated risks. They also called for stronger enforcement against illicit trade and youth access while preserving regulatory distinctions between combustible and smoke-free products.

The author argues that tobacco harm reduction (THR) should extend beyond helping current smokers switch to lower-risk nicotine products. US data show stable overall nicotine use alongside declining smoking and rising vaping, particularly among young adults. The author interprets these trends as suggesting that vaping may divert some people from smoking, although population trends alone cannot establish causation. THR could therefore include switching, maintaining smoking abstinence, and preventing smoking among would-be smokers. Whether vaping benefits never-smokers depends on whether they would otherwise smoke or remain nicotine-free. The author recommends broader messaging, research, and population models examining these counterfactuals to sustain THR’s relevance as cigarette smoking declines.

Ian Irvine argues that Canada’s restrictions on nicotine pouches undermine smoking cessation by making lower-risk alternatives harder to buy than cigarettes. He criticizes the Ontario Tobacco Research Unit’s opposition to nicotine substitution, advocating harm reduction rather than eliminating all nicotine use. Citing vaping initiatives in New Zealand and the UK, alongside declining smoking rates in Sweden and Norway, he urges Ottawa to improve access to pouches, vapes and heated tobacco products. Although nicotine causes dependence, Irvine maintains that these alternatives pose substantially lower health risks than smoking. The article discloses that some of his research received tobacco-policy foundation funding and that nicotine producers covered conference expenses.

Recent arrests in Hyderabad reveal that India’s vape ban has not prevented teenagers from accessing e-cigarettes through illicit suppliers. The article argues that prohibition sustains an underground market lacking age checks, product standards and marketing oversight, while denying adult smokers legal access to potentially less harmful alternatives to cigarettes. It advocates distinguishing youth protection from adult harm reduction through regulation, including age verification, advertising restrictions and penalties for sales to minors. Enforcement remains necessary, but success should be measured by reduced underage access and smoking-related harm, not raids or seizures. A regulated approach, the author suggests, could offer greater oversight than a blanket ban.

The UK’s Vaping Products Duty began October 1, charging £2.20 per 10ml of vaping liquid, including nicotine-free products. Duty stamps become mandatory for all products sold from April 1, 2027, after a grace period for existing stock. Non-compliance risks seizures, fines and criminal penalties. The government aims to discourage vaping among young people and nonsmokers, alongside higher tobacco duties. Industry representatives warn higher prices could drive consumers toward smoking or illicit products and increase retailers’ compliance burdens. The duty is projected to raise over £550 million annually by 2030–31, while £30 million annually through 2028–29 will support enforcement against illicit and underage tobacco and vape sales.

Easthampton became Massachusetts’ 25th municipality to adopt a lifetime nicotine-sales ban for younger generations, including noncombustible products. The author argues these policies conflate nicotine with smoking’s combustion-related harms and undermine harm reduction. Nicotine is addictive and carries cardiovascular and adolescent risks, but research suggests potential cognitive benefits, though therapeutic evidence remains preliminary. Comparing nicotine with caffeine and accepted nicotine-replacement therapies, the text criticizes restrictions on adult choice and the goal of eliminating nicotine use rather than smoking-related disease. It also warns that prohibition could encourage poorly studied, potentially stronger synthetic alternatives. The author advocates distinguishing nicotine from cigarettes and weighing its risks and benefits rather than treating it as inherently unacceptable.

The article portrays FDA tobacco director Bret Koplow as shifting regulation toward harm reduction after years of approval backlogs and limited support for cigarette alternatives. Speaking at a tobacco retailers’ conference, Koplow advocated cooperation with manufacturers and retailers to protect minors, accelerate authorization of scientifically supported lower-risk products for adults, and combat illicit e-cigarettes. His authorization of vaping and nicotine pouch products has drawn praise from industry and opposition from public health groups. Koplow emphasizes that no tobacco product is safe and quitting is healthiest, but completely switching from cigarettes to FDA-authorized, noncombustible alternatives can reduce exposure to toxic and cancer-causing chemicals.

The European Parliament’s public health committee approved a non-binding cancer policy report calling for higher, converging minimum taxes on all tobacco and nicotine products, while favouring labelling and awareness measures for alcohol and ultra-processed foods. Critics, including Czech MEP Tomáš Kubín, argue this approach ignores differing product risks, undermines harm reduction and conflicts with Parliament’s recent cardiovascular policy. They advocate evidence-based regulation, strict protections for minors and differentiated taxes encouraging healthier alternatives. Health economist Franco Sassi also calls for smarter food taxation to reduce cancer risks. The article urges Parliament to correct these perceived inconsistencies during the expected October–November plenary vote.

The text argues that growing evidence supports tobacco harm reduction products, especially e-cigarettes, as alternatives for adult smokers. It cites a Cochrane review of nine trials finding vaping more effective than traditional nicotine replacement therapies for quitting, with no serious harms identified in those trials. It also describes FDA authorization of reduced-risk marketing claims for ZYN nicotine pouches. The author contends that restrictive policies discourage cessation and fuel illicit markets, while cigarette smoking causes substantial mortality and economic costs. The text urges clinicians and policymakers to prioritize scientific evidence over stigma and prohibition, arguing that access to lower-risk nicotine products could improve public health.

Follow the funding trail and the nicotine debate starts to look less independent than it should. EU-backed NGOs campaigning in support of the Commission’s preferred agenda raise questions about circular influence, transparency and who gets treated as a credible voice. That matters because policy on vaping, pouches and other smoke-free products affects millions of adults who smoke. Public health decisions should be open about evidence, interests and funding — especially when they shape access to lower-risk alternatives.